BioSpace News Archive

Atmofizer Technologies Inc. is pleased to announce the latest testing performed by a third-party laboratory on Atmofizer ONE technology demonstrated a greater than 4-log reduction ( > 99.99%) in specifically targeted microorganisms, including gram-positive bacteria, gram-negative bacteria, and enveloped virus.

BioLife Solutions, Inc. (NASDAQ: BLFS) (“BioLife” or the “Company”) today announced the appointment of Timothy L. Moore to its board of directors, increasing board membership to six.

Baxter International Inc. (NYSE:BAX), a global medtech leader, announces the national expansion of its partnership with international not-for-profit organization The Links, Incorporated (The Links) to continue bringing awareness and resources for the disproportionate challenges affecting Black Americans related to kidney health.

Mycovia Pharmaceuticals, Inc. today announced the publication of its phase 3 ultraVIOLET study evaluating the efficacy and safety of VIVJOA™.

Sun Nuclear, a wholly-owned subsidiary of Mirion Technologies, Inc., announced its ATOM® Phantom product line will play a vital role in the first of a series of NASA missions aimed at enabling human exploration to the Moon and Mars.

UltraSight , an Israeli-based digital health pioneer transforming cardiac imaging through the power of artificial intelligence, announced it has obtained a CE Mark for its AI guidance software for cardiac ultrasound.

Celsius Therapeutics today announced the appointment of Sarah Grant, M.D., as chief medical officer.

Based on promising research conducted at Terasaki Institute for Biomedical Innovation (TIBI) the Company is pleased to announce that it has selected its final lead drug candidate from a short list of six DMT analogue molecules and intends to submit a provisional patent in Q4, 2022 detailing the novel uses and dosage forms of its lead candidate, and medical device for the treatment of primary open angle glaucoma (POAG).

Athos Therapeutics, Inc. (“Athos”) is a late-stage preclinical biotech company using Artificial Intelligence (AI) to develop small molecule therapeutics for immune-mediated diseases and cancer.

ElevateBio, LLC (ElevateBio) and the University of Pittsburgh today announced that they have entered into a long-term strategic partnership to accelerate the development of highly innovative cell and gene therapies.